Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another?

作者：Lakshmi P. Kocharla, AB Mongey · 发表于：Lupus · 年份：2009 · DOI：10.1177/0961203308093922 · 被引用次数：30 · 研究领域：Systemic Lupus Erythematosus Research、Monoclonal and Polyclonal Antibodies Research、Cytokine Signaling Pathways and Interactions

The use of TNF alpha (TNFalpha) inhibitors has made a strong impact on the management of rheumatoid and psoriatic arthritis, ankylosing spondylitis and Crohn disease. Side effects of these agents include the development of autoantibodies and a lupus-like syndrome (drug-related lupus, DRL). Here, a case of a patient who developed DRL while receiving infliximab therapy which resolved spontaneously upon discontinuation of the agent and did not recur with subsequent institution of adalimumab is described. A discussion on the possible pathogenic mechanisms involved in the development of drug-related autoimmunity and differences between the agents is also included.